Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

March 9, 2012 updated by: Galectin Therapeutics Inc.

A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of GM-CT-01 in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors

This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice. The primary reason for doing the study is to determine the safety of GM-CT-01 given alone and in combination with therapeutical dosage of 5-Fluorouracil, in patients who have advanced cancer that can be measured by CT scan.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

5-Fluorouracil is a chemotherapy drug commonly used in cancer patients. Patients with different type of solid tumors who have failed standard, approved treatments can be enrolled in the study. Escalated doses of GM-CT-01 will be given alone in Cycle 1, and in combination with 5-fluorouracil in cycle 2. Patients will be on study for approximately 60 days for determination of safety. However, with patient consent treatment can continue until disease progression is determined by CT scan. The study secondary reason is to determine whether treatment has stabilize the tumors or change it in size (get bigger, smaller or stay the same)after Cycle 2 and any additional cycles of treatment.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Jacksonville, Florida, United States, 32207
        • Florida Oncology Associates
    • Louisiana
      • New Orleans, Louisiana, United States, 70121
        • Ochsner Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan Comprehensive Cancer Center
    • New Hampshire
      • Lebanon, New Hampshire, United States, 03756
        • Dartmouth-Hitchcock Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • The subject is able to give informed consent to participate in this trial (including all procedures and follow-up visits).
  • The subject is male or female at least 18 years of age.
  • The subject has a documented histologic or cytologic recurrent or metastatic solid tumor that is not amenable to curative surgery, radiotherapy, or conventional chemotherapy of proven value.
  • Subjects must have completed previous therapy (chemotherapeutic agents or other therapies including radiation) at least 4 weeks prior to study entry.
  • Following major surgery (e.g. laparotomy), > 4 weeks must have elapsed and subjects must have recovered from effects.
  • Following minor surgery (does not include insertion of vascular access device), > 2 weeks must have elapsed.
  • ECOG performance status of 0-2.
  • The subject has a life expectancy of at least 12 weeks.
  • Female subjects must be post-menopausal, surgically sterile, or using effective contraception.

Laboratory values prior to administration of study drug:

  • If female and not post-menopausal, the subject has a negative pregnancy test.
  • Liver function studies: AST and ALT < 2.5 times the upper limit of normal (ULN); total bilirubin < 1.5
  • Hematopoietic parameters: WBC > 3000 per mm3; Granulocyte count > 1,500 per mm3; Platelet count > 100,000 per mm3
  • Renal: Creatinine < or = ULN
  • Pulmonary: Dlco > or = 60% of predicted

Exclusion Criteria:

  • If female, the subject is pregnant or breast feeding.
  • Central nervous system (CNS) metastases or primary CNS tumors.
  • The subject has a known hypersensitivity to GM-CT-01 or any of its components.
  • The subject has congestive heart failure or any other medical condition that could be adversely affected by intravenous infusion of up to approximately 200 mL of fluid over 60 minutes.
  • The subject is currently abusing alcohol and/or illicit drugs.
  • The subject has other significant medical, psychiatric, or social conditions which, in the investigators' opinion, may compromise the subject's safety in participating in this study.
  • In the investigators' judgment, the subject would be unreliable in adhering to the study visit schedule or other study requirements.
  • The subject is currently enrolled in a clinical trial or has participated in a clinical trial within the 30 days prior to entry into this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Safety
Time Frame: 60 days - two cycles of treatment
60 days - two cycles of treatment

Secondary Outcome Measures

Outcome Measure
Time Frame
Tumor progression
Time Frame: CT imaging at 60 days
CT imaging at 60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Galectin Therapeutics Inc.

Investigators

  • Study Director: Marilyn C Pike, M.D., Ph.D., Consultant to Pro-Pharmaceuticals, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2003

Primary Completion (ACTUAL)

April 1, 2005

Study Completion (ACTUAL)

September 1, 2006

Study Registration Dates

First Submitted

February 14, 2003

First Submitted That Met QC Criteria

February 14, 2003

First Posted (ESTIMATE)

February 17, 2003

Study Record Updates

Last Update Posted (ESTIMATE)

March 12, 2012

Last Update Submitted That Met QC Criteria

March 9, 2012

Last Verified

March 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DAVFU-001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on GM-CT-01

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe